BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38271254)

  • 21. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total-Body
    Pomykala KL; Czernin J; Grogan TR; Armstrong WR; Williams J; Calais J
    J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnostic accuracy of
    Rajwa P; Heidenreich J; Drzezga A; Schmidt M; Shariat SF; Heidenreich A
    Prostate; 2024 Jan; 84(1):74-78. PubMed ID: 37750292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective evaluation of
    Dong L; Zhu Y; Xin M; Dong B; Pan J; Liu J; Amend SR; Xue W; Pienta KJ; Rowe SP
    Med Oncol; 2020 Sep; 37(10):89. PubMed ID: 32920666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Multicenter Prospective Clinical Trial of
    McCarthy M; Francis R; Tang C; Watts J; Campbell A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
    Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential utility of [
    Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical consequences of routine
    Zacho HD; Nalliah S; Petersen A; Petersen LJ
    Scand J Urol; 2022; 56(5-6):353-358. PubMed ID: 36073096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Head-to-head comparison of [
    Ballal S; Yadav MP; Roesch F; Satapathy S; Moon ES; Martin M; Wakade N; Sheokand P; Tripathi M; Chandekar KR; Agarwal S; Sahoo RK; Rastogi S; Bal C
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):233-244. PubMed ID: 37642703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 68 Ga-FAPI PET/CT Detected Non-PSMA/FDG-Avid Primary Tumor in De Novo Metastatic Prostate Cancer.
    Pang Y; Meng T; Xu W; Shang Q; Chen H
    Clin Nucl Med; 2022 Dec; 47(12):1108-1111. PubMed ID: 35961368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective intra-individual comparison of [
    Lawal IO; Mokoala KMG; Mahapane J; Kleyhans J; Meckel M; Vorster M; Ebenhan T; Rösch F; Sathekge MM
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection efficacy of [
    Rosar F; Khreish F; Marlowe RJ; Schaefer-Schuler A; Burgard C; Maus S; Petto S; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2899-2909. PubMed ID: 37148297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the clinical use of PET/CT with
    Ribeiro AMB; Lima ENP; Zequi SC
    Urol Oncol; 2021 Jan; 39(1):73.e9-73.e18. PubMed ID: 32861620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gallium-68-prostate-specific membrane antigen (
    van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective evaluation of the performance of [
    Abufaraj M; Grubmüller B; Zeitlinger M; Kramer G; Seitz C; Haitel A; Baltzer P; Hacker M; Wadsak W; Pfaff S; Wiatr T; Mitterhauser M; Shariat SF; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2169-2177. PubMed ID: 31254037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlations between whole body volumetric parameters of
    Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H
    Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of metabolic tumor volume and total lesion uptake measured using Ga-68 labelled prostate-specific membrane antigen PET/CT in primary staging of prostate cancer.
    Kubilay E; Akpinar Ç; Oǧuz ES; Araz MS; Soydal Ç; Baltacı S; Ürün Y; Süer E
    Urol Oncol; 2022 Sep; 40(9):408.e19-408.e25. PubMed ID: 35902300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
    Arslan E; Ergül N; Beyhan E; Erol Fenercioglu Ö; Sahin R; Cin M; Battal Havare S; Can Trabulus FD; Mermut Ö; Akbas S; Fikret Çermik T
    Nucl Med Commun; 2023 Apr; 44(4):284-290. PubMed ID: 36756767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.